Lyell Immunopharma (NASDAQ:LYEL) Announces Earnings Results

Lyell Immunopharma (NASDAQ:LYEL) posted its quarterly earnings results on Tuesday. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01, Zacks reports. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%.

Lyell Immunopharma Stock Down 4.0%

Shares of Lyell Immunopharma stock opened at $0.40 on Wednesday. The company has a market cap of $119.49 million, a P/E ratio of -0.51 and a beta of -0.25. Lyell Immunopharma has a 52-week low of $0.39 and a 52-week high of $2.88. The firm’s 50 day moving average price is $0.49 and its 200-day moving average price is $0.67.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a report on Wednesday, April 16th.

Insider Transactions at Lyell Immunopharma

In other news, CEO Lynn Seely purchased 175,000 shares of the stock in a transaction dated Friday, March 14th. The shares were purchased at an average cost of $0.61 per share, with a total value of $106,750.00. Following the completion of the purchase, the chief executive officer now directly owns 712,500 shares of the company’s stock, valued at approximately $434,625. The trade was a 32.56% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Charles W. Newton purchased 200,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $0.56 per share, with a total value of $112,000.00. Following the acquisition, the chief financial officer now owns 200,000 shares of the company’s stock, valued at approximately $112,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders acquired 768,640 shares of company stock valued at $449,508 in the last quarter. 25.10% of the stock is currently owned by corporate insiders.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.